Furoscix drug information

2 DOSAGE AND ADMINISTRATION FUROSCIX is not for chronic use and should be replaced with oral diuretics as soon as practical. ( 2.1 ) The FUROSCIX ReadyFlow™ is pre-filled to deliver 80 mg of furosemide subcutaneously in about 10 seconds. The single-use, On-body Infusor is pre-programmed to deliver 30 mg of furosemide subcutaneously over the first hour then 12.5 mg per hour for the subsequent 4 hours. ( 2.1 ) See Full Prescribing Information for important administration instructions. ( 2.2 ) 2.1 Recommended Dosage FUROSCIX is not for chronic use and should be replaced with oral diuretics as soon as practical. Adult Patients: FUROSCIX ReadyFlow: The FUROSCIX ReadyFlow is an autoinjector that delivers 80 mg of furosemide subcutaneously in about 10 seconds [see Clinical Pharmacology ( 12 )] . Adult and Pediatric Patients 43 kg and Above: On-body Infusor for FUROSCIX: The single-use, On-body Infusor with prefilled cartridge is pre-programmed to deliver 30 mg of furosemide subcutaneously over the first hour followed by 12.5 mg per hour for the subsequent 4 hours [see Use in Specific Populations ( 8.6 ) and Clinical Pharmacology ( 12 )]. 2.2 Important Administration Instructions Inspect the parenteral drug product through the autoinjector viewing window or the prefilled cartridge for the On-body Infusor prior to administration. FUROSCIX is a clear, colorless to slightly yellow solution. Do not use FUROSCIX if you see particles or the solution is discolored or cloudy [see Description ( 11 )] . FUROSCIX is intended for administration to the abdomen only. For each subcutaneous administration, rotate the site on the abdomen. Refer to the Instructions for Use for additional information. FUROSCIX ReadyFlow (Adult Patients) : ​Instruct patients to select and clean an injection site on the abdomen at least two inches away from the belly button (navel) and avoid skin that is irritated or broken and areas with scars or stretch marks. Pull the blue cap straight off the FUROSCIX ReadyFlow and then firmly push and hold against the skin until the yellow plunger rod stops moving and fills the viewing window, about 10 seconds. On-body Infusor for FUROSCIX (Adult and Pediatric Patients 43 kg and above) : The On-body Infusor for FUROSCIX is not compatible with use in an MRI setting. The On-body Infusor for FUROSCIX is intended for use in a setting where the patient can limit their activity for the duration of administration [see Warnings and Precautions ( 5.5 )] . Load the prefilled cartridge of furosemide into the On-body Infusor and close the cartridge holder. Peel away the adhesive liner on the On-body Infusor and apply onto a clean, dry area of the abdomen between the top of the beltline and the bottom of the ribcage that is not tender, bruised, red or indurated. The distance from the top of the beltline to the bottom of the ribcage should be at least 2 ½ inches. Start the injection by firmly pressing and releasing the blue start button. Do not remove until the injection is complete (signaled by the solid green status light, beeping sound, and the white plunger rod filling the cartridge window). In pediatric patients weighing at least 43 kg, FUROSCIX On-body Infusor must be administered by a healthcare provider or adult caregiver. Adult patients or caregivers should receive proper instruction in preparing and administering FUROSCIX before using the FUROSCIX On-body Infusor. 2.1 Recommended Dosage FUROSCIX is not for chronic use and should be replaced with oral diuretics as soon as practical. Adult Patients: FUROSCIX ReadyFlow: The FUROSCIX ReadyFlow is an autoinjector that delivers 80 mg of furosemide subcutaneously in about 10 seconds [see Clinical Pharmacology ( 12 )] . Adult and Pediatric Patients 43 kg and Above: On-body Infusor for FUROSCIX: The single-use, On-body Infusor with prefilled cartridge is pre-programmed to deliver 30 mg of furosemide subcutaneously over the first hour followed by 12.5 mg per hour for the subsequent 4 hours [see Use in Specific Populations ( 8.6 ) and Clinical Pharmacology ( 12 )]. 2.2 Important Administration Instructions Inspect the parenteral drug product through the autoinjector viewing window or the prefilled cartridge for the On-body Infusor prior to administration. FUROSCIX is a clear, colorless to slightly yellow solution. Do not use FUROSCIX if you see particles or the solution is discolored or cloudy [see Description ( 11 )] . FUROSCIX is intended for administration to the abdomen only. For each subcutaneous administration, rotate the site on the abdomen. Refer to the Instructions for Use for additional information. FUROSCIX ReadyFlow (Adult Patients) : ​Instruct patients to select and clean an injection site on the abdomen at least two inches away from the belly button (navel) and avoid skin that is irritated or broken and areas with scars or stretch marks. Pull the blue cap straight off the FUROSCIX ReadyFlow and then firmly push and hold against the skin until the yellow plunger rod stops moving and fills the viewing window, about 10 seconds. On-body Infusor for FUROSCIX (Adult and Pediatric Patients 43 kg and above) : The On-body Infusor for FUROSCIX is not compatible with use in an MRI setting. The On-body Infusor for FUROSCIX is intended for use in a setting where the patient can limit their activity for the duration of administration [see Warnings and Precautions ( 5.5 )] . Load the prefilled cartridge of furosemide into the On-body Infusor and close the cartridge holder. Peel away the adhesive liner on the On-body Infusor and apply onto a clean, dry area of the abdomen between the top of the beltline and the bottom of the ribcage that is not tender, bruised, red or indurated. The distance from the top of the beltline to the bottom of the ribcage should be at least 2 ½ inches. Start the injection by firmly pressing and releasing the blue start button. Do not remove until the injection is complete (signaled by the solid green status light, beeping sound, and the white plunger rod filling the cartridge window). In pediatric patients weighing at least 43 kg, FUROSCIX On-body Infusor must be administered by a healthcare provider or adult caregiver. Adult patients or caregivers should receive proper instruction in preparing and administering FUROSCIX before using the FUROSCIX On-body Infusor.

3 DOSAGE FORMS AND STRENGTHS Injection : 80 mg/mL as a clear, colorless to slightly yellow solution in a single-dose prefilled autoinjector. 80 mg/10 mL (8 mg/mL) as a clear to slightly yellow solution in a single-dose prefilled cartridge for use only with co-packaged single-use, On-body Infusor. Injection: 80 mg/mL in a single-dose prefilled autoinjector ( 3 ) 80 mg/10 mL (8 mg/mL) in a single-dose prefilled cartridge co-packaged with a single-use On-body Infusor. ( 3 )

4 CONTRAINDICATIONS FUROSCIX is contraindicated in: Patients with anuria. Patients with a history of hypersensitivity to furosemide, or any component of the FUROSCIX formulation. The On-body Infusor for FUROSCIX is contraindicated in patients with a history of hypersensitivity to medical adhesives Anuria ( 4 ) Hypersensitivity to furosemide, or components of FUROSCIX formulation ( 4 ) FUROSCIX On-body Infusor: Hypersensitivity to medical adhesives ( 4 )

5 WARNINGS AND PRECAUTIONS Fluid, Electrolyte, and Metabolic Abnormalities : Monitor serum electrolytes, CO 2 , BUN, creatinine, glucose, and uric acid. ( 5.1 ) Worsening Renal Function : Monitor for dehydration and azotemia. ( 5.2 ) Ototoxicity : Avoid higher than recommended doses. ( 5.3 , 7.1 ) Acute Urinary Retention : Monitor patients with symptoms of urinary retention. ( 5.4 ) Incomplete Dosing : Fluid contact and certain patient movements during treatment may cause the On-body Infusor to prematurely terminate infusion. Ensure the patient or caregiver can detect and respond to alarms. ( 5.5 ) 5.1 Fluid, Electrolyte, and Metabolic Abnormalities Furosemide may cause fluid, electrolyte, and metabolic abnormalities such as hypovolemia, hypokalemia, azotemia, hyponatremia, hypochloremic alkalosis, hypomagnesemia, hypocalcemia, hyperglycemia, or hyperuricemia, particularly in patients receiving higher doses, patients with inadequate oral electrolyte intake, and in elderly patients. Excessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular thrombosis and embolism, particularly in elderly patients. Serum electrolytes, CO 2 , BUN, creatinine, glucose, and uric acid should be monitored frequently during furosemide therapy [see Use in Specific Populations ( 8.6 )] . 5.2 Worsening Renal Function Furosemide can cause dehydration and azotemia. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, discontinue furosemide [see Clinical Pharmacology ( 12.3 )]. 5.3 Ototoxicity Cases of tinnitus and reversible or irreversible hearing impairment and deafness have been reported with furosemide. Reports usually indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, the use of higher than recommended doses, hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs. If the physician elects to use high-dose parenteral therapy, controlled intravenous infusion is advisable (for adults, an infusion rate not exceeding 4 mg furosemide per minute has been used) [see Drug Interactions ( 7.1 )]. 5.4 Acute Urinary Retention In patients with severe symptoms of urinary retention (because of bladder emptying disorders, prostatic hyperplasia, urethral narrowing), the administration of furosemide can cause acute urinary retention related to increased production and retention of urine. These patients require careful monitoring, especially during the initial stages of treatment. 5.5 Incomplete Dosing The FUROSCIX ReadyFlow should be held against the abdomen until the yellow plunger rod stops moving and fills the viewing window. This may take about 10 seconds. The On-body Infusor for FUROSCIX should not be allowed to get wet from water or any other fluids (blood or drug product). Fluid contact with the circuit board can lead to device errors and premature termination of infusion. The On-body Infusor for FUROSCIX is intended for use in a setting where the patient can limit their activity for the duration of administration. Certain patient movements may cause interruption of device adherence to skin and premature termination of infusion. The On-body Infusor for FUROSCIX should only be administered in settings where alarms can be detected and responded to in order to ensure a complete dose is administered [see Dosage and Administration ( 2.2 )] . 5.1 Fluid, Electrolyte, and Metabolic Abnormalities Furosemide may cause fluid, electrolyte, and metabolic abnormalities such as hypovolemia, hypokalemia, azotemia, hyponatremia, hypochloremic alkalosis, hypomagnesemia, hypocalcemia, hyperglycemia, or hyperuricemia, particularly in patients receiving higher doses, patients with inadequate oral electrolyte intake, and in elderly patients. Excessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular thrombosis and embolism, particularly in elderly patients. Serum electrolytes, CO 2 , BUN, creatinine, glucose, and uric acid should be monitored frequently during furosemide therapy [see Use in Specific Populations ( 8.6 )] . 5.2 Worsening Renal Function Furosemide can cause dehydration and azotemia. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, discontinue furosemide [see Clinical Pharmacology ( 12.3 )]. 5.3 Ototoxicity Cases of tinnitus and reversible or irreversible hearing impairment and deafness have been reported with furosemide. Reports usually indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, the use of higher than recommended doses, hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs. If the physician elects to use high-dose parenteral therapy, controlled intravenous infusion is advisable (for adults, an infusion rate not exceeding 4 mg furosemide per minute has been used) [see Drug Interactions ( 7.1 )]. 5.4 Acute Urinary Retention In patients with severe symptoms of urinary retention (because of bladder emptying disorders, prostatic hyperplasia, urethral narrowing), the administration of furosemide can cause acute urinary retention related to increased production and retention of urine. These patients require careful monitoring, especially during the initial stages of treatment. 5.5 Incomplete Dosing The FUROSCIX ReadyFlow should be held against the abdomen until the yellow plunger rod stops moving and fills the viewing window. This may take about 10 seconds. The On-body Infusor for FUROSCIX should not be allowed to get wet from water or any other fluids (blood or drug product). Fluid contact with the circuit board can lead to device errors and premature termination of infusion. The On-body Infusor for FUROSCIX is intended for use in a setting where the patient can limit their activity for the duration of administration. Certain patient movements may cause interruption of device adherence to skin and premature termination of infusion. The On-body Infusor for FUROSCIX should only be administered in settings where alarms can be detected and responded to in order to ensure a complete dose is administered [see Dosage and Administration ( 2.2 )] .

6 ADVERSE REACTIONS The following important adverse reactions are discussed elsewhere in the labeling: Fluid, Electrolyte, and Metabolic Abnormalities [see Warnings and Precautions ( 5.1 )]. Ototoxicity [see Warnings and Precautions ( 5.3 )] The following adverse reactions associated with the use of furosemide were identified in clinical trials or post-marketing reports. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably, or to establish a causal relationship to drug exposure. Adverse reactions are categorized below by organ system and listed by decreasing severity. Gastrointestinal System Reactions : pancreatitis, jaundice (intrahepatic cholestatic jaundice), increased liver enzymes, anorexia, oral and gastric irritation, cramping, diarrhea, constipation, nausea, vomiting. Systemic Hypersensitivity Reactions : severe anaphylactic or anaphylactoid reactions (e.g., with shock), systemic vasculitis, interstitial nephritis, necrotizing angiitis. Central Nervous System Reactions : tinnitus and hearing loss, paresthesias, vertigo, dizziness, headache, blurred vision, xanthopsia. Hematologic Reactions : aplastic anemia, thrombocytopenia, agranulocytosis, hemolytic anemia, leukopenia, anemia, eosinophilia. Dermatologic Hypersensitivity Reactions : toxic epidermal necrolysis, Stevens-Johnson Syndrome, erythema multiforme, drug rash with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis, exfoliative dermatitis, bullous pemphigoid, purpura, photosensitivity, rash. Cardiovascular Reactions : orthostatic hypotension, increase in cholesterol and triglyceride serum levels. Administration Site and Skin Reactions : administration site erythema, bruising, edema, mass, pruritus, and pain. Other Reactions : glycosuria, muscle spasm, weakness, restlessness, urinary bladder spasm, thrombophlebitis, transient injection site pain following intramuscular injection, fever. The most common adverse reactions during treatment with FUROSCIX were administration site and skin reactions: erythema, bruising, edema and pain. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact MannKind Corporation at 1-877-323-8505 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

7 DRUG INTERACTIONS Aminoglycoside antibiotics : Increased potential ototoxicity of the antibiotics. Avoid combination. ( 7.1 ) Ethacrynic acid : Risk of ototoxicity. Avoid combination ( 7.1 ) Salicylates : Risk of salicylate toxicity. ( 7.1 ) Cisplatin and nephrotoxic drugs : Risk of ototoxicity and nephrotoxicity. ( 7.1 ) Lithium : Risk of lithium toxicity. ( 7.1 ) Renin-angiotensin inhibitors : Increased risk of hypotension and renal failure. ( 7.1 ) Adrenergic blocking drugs : Risk of potentiation. ( 7.1 ) Drugs undergoing renal tubular secretion : Risk of toxicity potentiation. ( 7.1 ) See 17 for PATIENT COUNSELING INFORMATION . 7.1 Effects of Furosemide on Other Drugs Drug/Substance Class or Name Drug Interaction Effect Recommendations Aminoglycoside antibiotics Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function [see Warnings and Precautions ( 5.3 )]. Avoid combination except in life-threatening situations. Ethacrynic acid Possibility of ototoxicity [see Warnings and Precautions ( 5.3 )]. Avoid concomitant use with ethacrynic acid. Salicylates May experience salicylate toxicity at lower doses because of competitive renal excretory sites. Monitor for symptoms of salicylate toxicity. Cisplatin There is a risk of ototoxic effects if cisplatin and furosemide are given concomitantly [see Warnings and Precautions ( 5.3 )]. Administer furosemide at lower doses and with positive fluid balance when used to achieve forced diuresis during cisplatin treatment. Monitor renal function. Cisplatin and nephrotoxic drugs Nephrotoxicity Paralytic agents Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine. Monitor for skeletal muscle effect. Lithium Furosemide reduces lithium’s renal clearance and add a high-risk of lithium toxicity. Avoid concomitant use with lithium. Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers May lead to severe hypotension and deterioration in renal function, including renal failure. Monitor for changes in blood pressure and renal function and interrupt or reduce the dosage of furosemide, angiotensin converting enzyme inhibitors, or angiotensin receptor blockers if needed. Antihypertensive drugs Furosemide may add to or potentiate the therapeutic effect of other antihypertensive drugs. Monitor for changes in blood pressure and adjust the dose of other antihypertensive drugs if needed. Adrenergic blocking drugs or peripheral adrenergic blocking drugs Potentiation occurs. Monitor for changes in blood pressure and adjust the dose of adrenergic blocking drugs if needed. Norepinephrine Furosemide may decrease arterial responsiveness (vasoconstricting effect) to norepinephrine. Monitor blood pressure (or mean arterial pressure). Chloral hydrate In isolated cases, intravenous administration of furosemide within 24 hours of taking chloral hydrate may lead to flushing, sweating attacks, restlessness, nausea, increase in blood pressure, and tachycardia. Concomitant use with chloral hydrate is not recommended. Methotrexate and other drugs undergoing renal tubular secretion Furosemide may decrease renal elimination of other drugs that undergo tubular secretion. High-dose treatment of furosemide may result in elevated serum levels of these drugs and may potentiate their toxicity. Monitor serum levels of drugs undergoing renal tubular secretion and adjust the dose if needed. Cephalosporin Furosemide can increase the risk of cephalosporin-induced nephrotoxicity even in the setting of minor or transient renal impairment. Monitor for changes in renal function. Cyclosporine Increased risk of gouty arthritis secondary to furosemide-induced hyperuricemia and cyclosporine impairment of renal urate excretion. Monitor serum urate levels. Thyroid hormones High-doses (> 80 mg) of furosemide may inhibit the binding of thyroid hormones to carrier proteins and result in transient increase in free thyroid hormones, followed by an overall decrease in total thyroid hormone levels. Monitor the total thyroid hormone levels. 7.2 Effect of Other Drugs on Furosemide Drug/Substance Class or Name Drug Interaction Effect Recommendations Phenytoin Phenytoin interferes directly with renal action of furosemide. Monitor diuretic effects of furosemide and adjust the dose of furosemide if needed. Methotrexate and other drugs undergoing renal tubular secretion May reduce the effect of furosemide. High-dose treatment of methotrexate and these other drugs may result in elevated serum levels of furosemide and may potentiate the toxicity of furosemide. Monitor for enhanced toxicity of furosemide. Indomethacin Coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis. Indomethacin may also affect plasma renin levels, aldosterone excretion, and renin profile evaluation. Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved. 7.1 Effects of Furosemide on Other Drugs Drug/Substance Class or Name Drug Interaction Effect Recommendations Aminoglycoside antibiotics Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function [see Warnings and Precautions ( 5.3 )]. Avoid combination except in life-threatening situations. Ethacrynic acid Possibility of ototoxicity [see Warnings and Precautions ( 5.3 )]. Avoid concomitant use with ethacrynic acid. Salicylates May experience salicylate toxicity at lower doses because of competitive renal excretory sites. Monitor for symptoms of salicylate toxicity. Cisplatin There is a risk of ototoxic effects if cisplatin and furosemide are given concomitantly [see Warnings and Precautions ( 5.3 )]. Administer furosemide at lower doses and with positive fluid balance when used to achieve forced diuresis during cisplatin treatment. Monitor renal function. Cisplatin and nephrotoxic drugs Nephrotoxicity Paralytic agents Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine. Monitor for skeletal muscle effect. Lithium Furosemide reduces lithium’s renal clearance and add a high-risk of lithium toxicity. Avoid concomitant use with lithium. Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers May lead to severe hypotension and deterioration in renal function, including renal failure. Monitor for changes in blood pressure and renal function and interrupt or reduce the dosage of furosemide, angiotensin converting enzyme inhibitors, or angiotensin receptor blockers if needed. Antihypertensive drugs Furosemide may add to or potentiate the therapeutic effect of other antihypertensive drugs. Monitor for changes in blood pressure and adjust the dose of other antihypertensive drugs if needed. Adrenergic blocking drugs or peripheral adrenergic blocking drugs Potentiation occurs. Monitor for changes in blood pressure and adjust the dose of adrenergic blocking drugs if needed. Norepinephrine Furosemide may decrease arterial responsiveness (vasoconstricting effect) to norepinephrine. Monitor blood pressure (or mean arterial pressure). Chloral hydrate In isolated cases, intravenous administration of furosemide within 24 hours of taking chloral hydrate may lead to flushing, sweating attacks, restlessness, nausea, increase in blood pressure, and tachycardia. Concomitant use with chloral hydrate is not recommended. Methotrexate and other drugs undergoing renal tubular secretion Furosemide may decrease renal elimination of other drugs that undergo tubular secretion. High-dose treatment of furosemide may result in elevated serum levels of these drugs and may potentiate their toxicity. Monitor serum levels of drugs undergoing renal tubular secretion and adjust the dose if needed. Cephalosporin Furosemide can increase the risk of cephalosporin-induced nephrotoxicity even in the setting of minor or transient renal impairment. Monitor for changes in renal function. Cyclosporine Increased risk of gouty arthritis secondary to furosemide-induced hyperuricemia and cyclosporine impairment of renal urate excretion. Monitor serum urate levels. Thyroid hormones High-doses (> 80 mg) of furosemide may inhibit the binding of thyroid hormones to carrier proteins and result in transient increase in free thyroid hormones, followed by an overall decrease in total thyroid hormone levels. Monitor the total thyroid hormone levels. 7.2 Effect of Other Drugs on Furosemide Drug/Substance Class or Name Drug Interaction Effect Recommendations Phenytoin Phenytoin interferes directly with renal action of furosemide. Monitor diuretic effects of furosemide and adjust the dose of furosemide if needed. Methotrexate and other drugs undergoing renal tubular secretion May reduce the effect of furosemide. High-dose treatment of methotrexate and these other drugs may result in elevated serum levels of furosemide and may potentiate the toxicity of furosemide. Monitor for enhanced toxicity of furosemide. Indomethacin Coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis. Indomethacin may also affect plasma renin levels, aldosterone excretion, and renin profile evaluation. Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved. Table text from source: | Drug/Substance Class or Name | Drug Interaction Effect | Recommendations | Aminoglycoside antibiotics | Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function [see Warnings and Precautions ( 5.3)]. | Avoid combination except in life-threatening situations. | Ethacrynic acid | Possibility of ototoxicity [see Warnings and Precautions ( 5.3)]. | Avoid concomitant use with ethacrynic acid. | Salicylates | May experience salicylate toxicity at lower doses because of competitive renal excretory sites. | Monitor for symptoms of salicylate toxicity. | Cisplatin | There is a risk of ototoxic effects if cisplatin and furosemide are given concomitantly [see Warnings and Precautions ( 5.3)]. | Administer furosemide at lower doses and with positive fluid balance when used to achieve forced diuresis during cisplatin treatment. Monitor renal function. | Cisplatin and nephrotoxic drugs | Nephrotoxicity | Paralytic agents | Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine. | Monitor for skeletal muscle effect. | Lithium | Furosemide reduces lithium’s renal clearance and add a high-risk of lithium toxicity. | Avoid concomitant use with lithium. | Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers | May lead to severe hypotension and deterioration in renal function, including renal failure. | Monitor for changes in blood pressure and renal function and interrupt or reduce the dosage of furosemide, angiotensin converting enzyme inhibitors, or angiotensin receptor blockers if needed. | Antihypertensive drugs | Furosemide may add to or potentiate the therapeutic effect of other antihypertensive drugs. | Monitor for changes in blood pressure and adjust the dose of other antihypertensive drugs if needed. | Adrenergic blocking drugs or peripheral adrenergic blocking drugs | Potentiation occurs. | Monitor for changes in blood pressure and adjust the dose of adrenergic blocking drugs if needed. | Norepinephrine | Furosemide may decrease arterial responsiveness (vasoconstricting effect) to norepinephrine. | Monitor blood pressure (or mean arterial pressure). | Chloral hydrate | In isolated cases, intravenous administration of furosemide within 24 hours of taking chloral hydrate may lead to flushing, sweating attacks, restlessness, nausea, increase in blood pressure, and tachycardia. | Concomitant use with chloral hydrate is not recommended. | Methotrexate and other drugs undergoing renal tubular secretion | Furosemide may decrease renal elimination of other drugs that undergo tubular secretion. High-dose treatment of furosemide may result in elevated serum levels of these drugs and may potentiate their toxicity. | Monitor serum levels of drugs undergoing renal tubular secretion and adjust the dose if needed. | Cephalosporin | Furosemide can increase the risk of cephalosporin-induced nephrotoxicity even in the setting of minor or transient renal impairment. | Monitor for changes in renal function. | Cyclosporine | Increased risk of gouty arthritis secondary to furosemide-induced hyperuricemia and cyclosporine impairment of renal urate excretion. | Monitor serum urate levels. | Thyroid hormones | High-doses (> 80 mg) of furosemide may inhibit the binding of thyroid hormones to carrier proteins and result in transient increase in free thyroid hormones, followed by an overall decrease in total thyroid hormone levels. | Monitor the total thyroid hormone levels. | Drug/Substance Class or Name | Drug Interaction Effect | Recommendations | Phenytoin | Phenytoin interferes directly with renal action of furosemide. | Monitor diuretic effects of furosemide and adjust the dose of furosemide if needed. | Methotrexate and other drugs undergoing renal tubular secretion | May reduce the effect of furosemide. High-dose treatment of methotrexate and these other drugs may result in elevated serum levels of furosemide and may potentiate the toxicity of furosemide. | Monitor for enhanced toxicity of furosemide. | Indomethacin | Coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis. Indomethacin may also affect plasma renin levels, aldosterone excretion, and renin profile evaluation. | Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved. | Drug/Substance Class or Name | Drug Interaction Effect | Recommendations | Aminoglycoside antibiotics | Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function [see Warnings and Precautions ( 5.3)]. | Avoid combination except in life-threatening situations. | Ethacrynic acid | Possibility of ototoxicity [see Warnings and Precautions ( 5.3)]. | Avoid concomitant use with ethacrynic acid. | Salicylates | May experience salicylate toxicity at lower doses because of competitive renal excretory sites. | Monitor for symptoms of salicylate toxicity. | Cisplatin | There is a risk of ototoxic effects if cisplatin and furosemide are given concomitantly [see Warnings and Precautions ( 5.3)]. | Administer furosemide at lower doses and with positive fluid balance when used to achieve forced diuresis during cisplatin treatment. Monitor renal function. | Cisplatin and nephrotoxic drugs | Nephrotoxicity | Paralytic agents | Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine. | Monitor for skeletal muscle effect. | Lithium | Furosemide reduces lithium’s renal clearance and add a high-risk of lithium toxicity. | Avoid concomitant use with lithium. | Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers | May lead to severe hypotension and deterioration in renal function, including renal failure. | Monitor for changes in blood pressure and renal function and interrupt or reduce the dosage of furosemide, angiotensin converting enzyme inhibitors, or angiotensin receptor blockers if needed. | Antihypertensive drugs | Furosemide may add to or potentiate the therapeutic effect of other antihypertensive drugs. | Monitor for changes in blood pressure and adjust the dose of other antihypertensive drugs if needed. | Adrenergic blocking drugs or peripheral adrenergic blocking drugs | Potentiation occurs. | Monitor for changes in blood pressure and adjust the dose of adrenergic blocking drugs if needed. | Norepinephrine | Furosemide may decrease arterial responsiveness (vasoconstricting effect) to norepinephrine. | Monitor blood pressure (or mean arterial pressure). | Chloral hydrate | In isolated cases, intravenous administration of furosemide within 24 hours of taking chloral hydrate may lead to flushing, sweating attacks, restlessness, nausea, increase in blood pressure, and tachycardia. | Concomitant use with chloral hydrate is not recommended. | Methotrexate and other drugs undergoing renal tubular secretion | Furosemide may decrease renal elimination of other drugs that undergo tubular secretion. High-dose treatment of furosemide may result in elevated serum levels of these drugs and may potentiate their toxicity. | Monitor serum levels of drugs undergoing renal tubular secretion and adjust the dose if needed. | Cephalosporin | Furosemide can increase the risk of cephalosporin-induced nephrotoxicity even in the setting of minor or transient renal impairment. | Monitor for changes in renal function. | Cyclosporine | Increased risk of gouty arthritis secondary to furosemide-induced hyperuricemia and cyclosporine impairment of renal urate excretion. | Monitor serum urate levels. | Thyroid hormones | High-doses (> 80 mg) of furosemide may inhibit the binding of thyroid hormones to carrier proteins and result in transient increase in free thyroid hormones, followed by an overall decrease in total thyroid hormone levels. | Monitor the total thyroid hormone levels. | Drug/Substance Class or Name | Drug Interaction Effect | Recommendations | Phenytoin | Phenytoin interferes directly with renal action of furosemide. | Monitor diuretic effects of furosemide and adjust the dose of furosemide if needed. | Methotrexate and other drugs undergoing renal tubular secretion | May reduce the effect of furosemide. High-dose treatment of methotrexate and these other drugs may result in elevated serum levels of furosemide and may potentiate the toxicity of furosemide. | Monitor for enhanced toxicity of furosemide. | Indomethacin | Coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis. Indomethacin may also affect plasma renin levels, aldosterone excretion, and renin profile evaluation. | Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.

Indications and Usage ( 1 ) 12/2025 Dosage and Administration ( 2 ) 7/2026 Warnings and Precautions, Incomplete Dosing ( 5.5 ) 7/2026

8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary Available data from published observational studies, case reports, and post marketing reports, from decades of use, have not demonstrated a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes with furosemide use during pregnancy. Untreated congestive heart failure and cirrhosis of the liver can lead to adverse outcomes for the mother and the fetus (see Clinical Considerations). In animal reproduction studies, furosemide has been shown to cause unexplained maternal deaths and abortions in rabbits when administered orally during organogenesis at 4 times a human i.v. dose of 80 mg based on body surface area (BSA) and oral bioavailability corrections, presumably secondary to volume depletion (see Data). FUROSCIX ReadyFlow contains benzyl alcohol (BA) as a preservative. Because BA is rapidly metabolized by a pregnant female, BA exposure in the fetus is unlikely. The estimated background risk for major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in the clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated Maternal and/or Embryo/fetal Risk Pregnant women with congestive heart failure are at increased risk for pre-term birth. Stroke volume and heart rate increase during pregnancy, increasing cardiac output, especially during the first trimester. Clinical classification of heart disease may worsen with pregnancy and lead to maternal death and/or stillbirth. Closely monitor pregnant patients for destabilization of their heart failure. Pregnant women with symptomatic cirrhosis generally have poor outcomes including hepatic failure, variceal hemorrhage, pre-term delivery, fetal growth restriction and maternal death. Outcomes are worse with coexisting esophageal varices. Carefully monitor pregnant women with cirrhosis of the liver. Data Animal Data The effects of furosemide on embryonic and fetal development and on pregnant dams were studied in mice, rats, and rabbits. Furosemide caused unexplained maternal deaths and abortions in the rabbit at the lowest dose of 25 mg/kg (approximately 4 times the human i.v. dose of 80 mg based on BSA and oral bioavailability corrections). In another study, a dose of 50 mg/kg (approximately 7 times a human i.v. dose of 80 mg based on BSA and oral bioavailability corrections) also caused maternal deaths and abortions when administered to rabbits between Days 12 and 17 of gestation. In a third study, none of the pregnant rabbits survived an oral dose of 100 mg/kg. Data from the above studies indicate fetal lethality that can precede maternal deaths. The results of the mouse study and one of the three rabbit studies also showed an increased incidence and severity of hydronephrosis (distention of the renal pelvis and, in some cases, of the ureters) in fetuses of treated dams as compared with the incidence of fetuses from the control group. 8.2 Lactation Risk Summary The presence of furosemide has been reported in human breast milk. There are no data on the effects on the breastfed infant or the effects on milk production. Doses of furosemide associated with clinically significant diuresis may impair milk production. FUROSCIX ReadyFlow contains benzyl alcohol (BA) as a preservative. Because BA is rapidly metabolized by a pregnant female, BA exposure in the breastfed neonate is unlikely. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for furosemide and any potential adverse effects on the breastfed infant from furosemide or from the underlying maternal condition. 8.4 Pediatric Use Safety and efficacy of the FUROSCIX ReadyFlow for pediatric use have not been established. The On-body Infusor for FUROSCIX is approved for the treatment of edema in pediatric patients weighing at least 43 kg with chronic heart failure or chronic kidney disease, including the nephrotic syndrome. FUROSCIX has not been studied in pediatric patients. Use of FUROSCIX for this indication is supported by: 1) efficacy, safety, and pharmacokinetic data of furosemide in adult and pediatric patients; 2) pharmacokinetic and pharmacodynamic data of FUROSCIX in adults with New York Heart Association (NYHA) Functional Classification Class II and Class III heart failure [see Clinical Pharmacology ( 12.2 , 12.3 )] ; and 3) population pharmacokinetic modeling which demonstrated no significant difference in furosemide exposure following FUROSCIX administration in a simulated pediatric population weighing 43 kg and above and aged 6 to <17 years compared to adult patients with chronic heart failure [see Clinical Pharmacology ( 12.3 )]. FUROSCIX is not approved for the treatment of edema in pediatric patients weighing less than 43 kg. 8.5 Geriatric Use Controlled clinical studies did not include sufficient numbers of subjects to determine whether subjects aged 65 and over respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for the elderly patients should be cautious, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. FUROSCIX is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Clinical Pharmacology ( 12.3 )]. 8.6 Renal Impairment Significantly reduced renal function can affect the response to furosemide. The FUROSCIX ReadyFlow and the On-body Infusor will deliver only an 80 mg dose of furosemide, and patients with significantly reduced renal function may require additional diuretic therapy. 8.7 Hepatic Impairment In patients with hepatic cirrhosis and ascites, sudden alterations of fluid and electrolyte balance may precipitate hepatic encephalopathy and coma. Treat such patients in a setting where clinical status and electrolyte balance can be carefully monitored. 8.1 Pregnancy Risk Summary Available data from published observational studies, case reports, and post marketing reports, from decades of use, have not demonstrated a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes with furosemide use during pregnancy. Untreated congestive heart failure and cirrhosis of the liver can lead to adverse outcomes for the mother and the fetus (see Clinical Considerations). In animal reproduction studies, furosemide has been shown to cause unexplained maternal deaths and abortions in rabbits when administered orally during organogenesis at 4 times a human i.v. dose of 80 mg based on body surface area (BSA) and oral bioavailability corrections, presumably secondary to volume depletion (see Data). FUROSCIX ReadyFlow contains benzyl alcohol (BA) as a preservative. Because BA is rapidly metabolized by a pregnant female, BA exposure in the fetus is unlikely. The estimated background risk for major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in the clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated Maternal and/or Embryo/fetal Risk Pregnant women with congestive heart failure are at increased risk for pre-term birth. Stroke volume and heart rate increase during pregnancy, increasing cardiac output, especially during the first trimester. Clinical classification of heart disease may worsen with pregnancy and lead to maternal death and/or stillbirth. Closely monitor pregnant patients for destabilization of their heart failure. Pregnant women with symptomatic cirrhosis generally have poor outcomes including hepatic failure, variceal hemorrhage, pre-term delivery, fetal growth restriction and maternal death. Outcomes are worse with coexisting esophageal varices. Carefully monitor pregnant women with cirrhosis of the liver. Data Animal Data The effects of furosemide on embryonic and fetal development and on pregnant dams were studied in mice, rats, and rabbits. Furosemide caused unexplained maternal deaths and abortions in the rabbit at the lowest dose of 25 mg/kg (approximately 4 times the human i.v. dose of 80 mg based on BSA and oral bioavailability corrections). In another study, a dose of 50 mg/kg (approximately 7 times a human i.v. dose of 80 mg based on BSA and oral bioavailability corrections) also caused maternal deaths and abortions when administered to rabbits between Days 12 and 17 of gestation. In a third study, none of the pregnant rabbits survived an oral dose of 100 mg/kg. Data from the above studies indicate fetal lethality that can precede maternal deaths. The results of the mouse study and one of the three rabbit studies also showed an increased incidence and severity of hydronephrosis (distention of the renal pelvis and, in some cases, of the ureters) in fetuses of treated dams as compared with the incidence of fetuses from the control group. 8.2 Lactation Risk Summary The presence of furosemide has been reported in human breast milk. There are no data on the effects on the breastfed infant or the effects on milk production. Doses of furosemide associated with clinically significant diuresis may impair milk production. FUROSCIX ReadyFlow contains benzyl alcohol (BA) as a preservative. Because BA is rapidly metabolized by a pregnant female, BA exposure in the breastfed neonate is unlikely. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for furosemide and any potential adverse effects on the breastfed infant from furosemide or from the underlying maternal condition. 8.4 Pediatric Use Safety and efficacy of the FUROSCIX ReadyFlow for pediatric use have not been established. The On-body Infusor for FUROSCIX is approved for the treatment of edema in pediatric patients weighing at least 43 kg with chronic heart failure or chronic kidney disease, including the nephrotic syndrome. FUROSCIX has not been studied in pediatric patients. Use of FUROSCIX for this indication is supported by: 1) efficacy, safety, and pharmacokinetic data of furosemide in adult and pediatric patients; 2) pharmacokinetic and pharmacodynamic data of FUROSCIX in adults with New York Heart Association (NYHA) Functional Classification Class II and Class III heart failure [see Clinical Pharmacology ( 12.2 , 12.3 )] ; and 3) population pharmacokinetic modeling which demonstrated no significant difference in furosemide exposure following FUROSCIX administration in a simulated pediatric population weighing 43 kg and above and aged 6 to <17 years compared to adult patients with chronic heart failure [see Clinical Pharmacology ( 12.3 )]. FUROSCIX is not approved for the treatment of edema in pediatric patients weighing less than 43 kg. 8.5 Geriatric Use Controlled clinical studies did not include sufficient numbers of subjects to determine whether subjects aged 65 and over respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for the elderly patients should be cautious, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. FUROSCIX is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Clinical Pharmacology ( 12.3 )]. 8.6 Renal Impairment Significantly reduced renal function can affect the response to furosemide. The FUROSCIX ReadyFlow and the On-body Infusor will deliver only an 80 mg dose of furosemide, and patients with significantly reduced renal function may require additional diuretic therapy. 8.7 Hepatic Impairment In patients with hepatic cirrhosis and ascites, sudden alterations of fluid and electrolyte balance may precipitate hepatic encephalopathy and coma. Treat such patients in a setting where clinical status and electrolyte balance can be carefully monitored.

10 OVERDOSAGE The principal signs and symptoms of overdose with FUROSCIX are dehydration, blood volume reduction, hypotension, electrolyte imbalance, hypokalemia and hypochloremic alkalosis, and are extensions of its diuretic action. The concentration of furosemide in biological fluids associated with toxicity or death is not known. Treatment of overdosage is supportive and consists of replacement of excessive fluid and electrolyte losses. Serum electrolytes, carbon dioxide level and blood pressure should be determined frequently. Adequate drainage must be assured in patients with urinary bladder outlet obstruction (such as prostatic hypertrophy). Hemodialysis does not accelerate furosemide elimination.

11 DESCRIPTION FUROSCIX (furosemide injection 80 mg/10 mL or 80 mg/mL) is a loop diuretic which is an anthranilic acid derivative. Chemically, it is 4-­chloro-­N-­furfuryl-­5-­sulfamoylanthranilic acid. Furosemide is a white to slightly yellow crystalline powder. It is sparingly soluble in alcohol, freely soluble in dilute alkali solutions and insoluble in dilute acids. The structural formula is as follows: Molecular Formula: C 12 H 11 ClN 2 O 5 S Molecular Weight: 330.75 g/mol FUROSCIX ReadyFlow : The ReadyFlow is a disposable, fixed single-dose, mechanical spring driven autoinjector. The ReadyFlow is preloaded with the prefilled syringe containing the drug and delivers 80 mg of furosemide in about 10 seconds. The single-dose prefilled FUROSCIX ReadyFlow contains 80 mg per 1 mL sterile, clear, colorless to slightly yellow, and non-pyrogenic furosemide solution. The pH of FUROSCIX for administration via the ReadyFlow, 7.7, differs from that of Furosemide Injection, USP. Autoinjector contains 1 mL of FUROSCIX ReadyFlow that contains 80 mg furosemide and the following inactive ingredients: benzyl alcohol (35 mg), hydrochloric acid for pH adjustment if needed, sodium hydroxide for pH adjustment if needed, tromethamine (9.7 mg), and water for injection (q.s.). On-body Infusor for FUROSCIX : The On-body Infusor for FUROSCIX is a wearable, single-use, electromechanical (battery powered, micro-processor controlled), on-body delivery system that is pre-programmed to deliver 80 mg of furosemide over 5-hours using a bi-phasic delivery profile. FUROSCIX for administration via the On-body Infusor is provided in a single-dose prefilled cartridge co-packaged with a single-use, On-body Infusor. The single-dose prefilled cartridge contains 80 mg per 10 mL sterile, clear, colorless to slightly yellow, and non-pyrogenic furosemide solution. The pH of FUROSCIX for administration via the On-body Infusor, 7.4, differs from that of Furosemide Injection, USP. Each 1 mL of FUROSCIX for administration via the On-body Infusor contains the following inactive ingredients: hydrochloric acid for pH adjustment if needed, sodium chloride (5.84 mg), sodium hydroxide for pH adjustment if needed, tris HCl (7.88 mg), and water for injection (q.s.). Structure

12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Furosemide primarily inhibits the reabsorption of sodium and chloride in the proximal and distal tubules and in the loop of Henle. The high degree of diuresis is largely due to the unique site of action. The action on the distal tubule is independent of any inhibitory effect on carbonic anhydrase and aldosterone. 12.2 Pharmacodynamics In healthy adults, subcutaneous administration of FUROSCIX (80 mg furosemide injection via the ReadyFlow) produced similar diuresis, natriuresis, and kaliuresis to intravenous administration (two 40 mg bolus doses separated by 120 minutes) at 6, 8, and 12 hours post-dose. The duration of diuretic effect with FUROSCIX ReadyFlow was up to 6 hours after initiation of dosing. In adult patients with NYHA Class II and Class III heart failure, subcutaneous administration of FUROSCIX (30 mg furosemide over the first hour followed by 12.5 mg per hour for the subsequent 4 hours, total 80 mg furosemide) produced similar diuresis and natriuresis to intravenous administration (two 40 mg bolus doses separated by 120 minutes) at 8 and 24 hours post-dose. The duration of diuretic effect with FUROSCIX On-body Infusor was up to 8 hours after initiation of dosing. 12.3 Pharmacokinetics Absorption In healthy adults, subcutaneous injection of FUROSCIX (80 mg furosemide injection via the ReadyFlow), the bioavailability was 107.3% (90% CI: 103.9, 110.8) relative to 80 mg intravenous furosemide (two 40‑mg bolus doses separated by 120 minutes) with a median (min-max) T max of 0.75 (0.5-1.5) hours. The pharmacokinetic parameters of FUROSCIX following subcutaneous injection via the ReadyFlow autoinjector are presented in Table 1 below: Table 1: Pharmacokinetic Data of FUROSCIX Following Subcutaneous Injection via the ReadyFlow Autoinjector (n = 19) Dose C max (ng/mL) AUC t (ng×hr/mL) T 1/2 (hr) AUC ∞ (ng×hr/mL) FUROSCIX: 80 mg injection via the ReadyFlow 4,530 ± 1,500 12,500 ± 4,010 2.2 ± 0.3 12,700 ± 4,120 Furosemide administered as 2 x 40 mg bolus doses intravenously, separated by 120 minutes (total dose: 80 mg furosemide) 10,100 ± 2,810 11,700 ± 3,450 1.9 ± 0.4 11,800 ± 3,510 In adult patients with NYHA Class II-III congestive heart failure, subcutaneous infusion of FUROSCIX (30 mg furosemide over the first hour followed by 12.5 mg per hour for the subsequent 4 hours, 80 mg furosemide total), the bioavailability was 99.6% (90% CI: 94.8, 104.8) relative to 80 mg intravenous furosemide (two 40-mg bolus doses separated by 120 minutes) with a median T max (min-max) of 4 (1.00 - 5.08) hours. The pharmacokinetic parameters of FUROSCIX following subcutaneous infusion via the On-body Infusor are presented in Table 2 below: Table 2: Pharmacokinetic Data of FUROSCIX Following Subcutaneous Infusion via the On-body Infusor (n = 15) Dose Cmax (ng/mL) AUCt (ng×hr/mL) T1/2 (hr) AUC∞ (ng×hr/mL) FUROSCIX: 30 mg subcutaneously infused over the first hour followed by 12.5 mg per hour for the subsequent 4 hours (total dose: 80 mg furosemide) 2,040 ± 449 13,000 ± 4,000 3.2 ± 0.9 13,100 ± 4,010 Furosemide administered as 2 x 40 mg bolus doses intravenously, separated by 120 minutes (total dose: 80 mg furosemide) 8,580 ± 2,540 13,000 ± 4,050 2.6 ± 0.3 13,200 ± 4,170 The impact of subcutaneous edema at the administration site of FUROSCIX on drug absorption is unknown. Distribution Furosemide is extensively bound to plasma proteins, mainly to albumin. Plasma concentrations ranging from 1 mcg per mL to 400 mcg per mL are 91% to 99% bound in healthy individuals. The unbound fraction averages 2.3% to 4.1% at therapeutic concentrations. Elimination The terminal half-life of furosemide is approximately 2 hours. Metabolism Furosemide glucuronide is the only or at least the major biotransformation product of furosemide in humans. Excretion Significantly more furosemide is excreted in urine following the intravenous injection than after the tablet or oral solution. Specific Populations Pediatric Patients FUROSCIX was not evaluated in a pediatric clinical study. Based on population pharmacokinetic modeling and simulation, pediatric patients aged 6 to <17 years and weighing 43 kg and above are predicted to have comparable exposures to adult patients following FUROSCIX administration using the FUROSCIX On-body Infusor. Geriatric Patients Furosemide binding to albumin may be reduced in elderly patients. Furosemide is predominantly excreted unchanged in the urine. The renal clearance of furosemide after intravenous administration in older healthy male subjects (60 to 70 years of age) is significantly less than in younger healthy male subjects (20 to 35 years of age). The initial diuretic effect of furosemide in older subjects is decreased relative to younger subjects [see Use in Specific Populations ( 8.5 )] . 12.1 Mechanism of Action Furosemide primarily inhibits the reabsorption of sodium and chloride in the proximal and distal tubules and in the loop of Henle. The high degree of diuresis is largely due to the unique site of action. The action on the distal tubule is independent of any inhibitory effect on carbonic anhydrase and aldosterone. 12.2 Pharmacodynamics In healthy adults, subcutaneous administration of FUROSCIX (80 mg furosemide injection via the ReadyFlow) produced similar diuresis, natriuresis, and kaliuresis to intravenous administration (two 40 mg bolus doses separated by 120 minutes) at 6, 8, and 12 hours post-dose. The duration of diuretic effect with FUROSCIX ReadyFlow was up to 6 hours after initiation of dosing. In adult patients with NYHA Class II and Class III heart failure, subcutaneous administration of FUROSCIX (30 mg furosemide over the first hour followed by 12.5 mg per hour for the subsequent 4 hours, total 80 mg furosemide) produced similar diuresis and natriuresis to intravenous administration (two 40 mg bolus doses separated by 120 minutes) at 8 and 24 hours post-dose. The duration of diuretic effect with FUROSCIX On-body Infusor was up to 8 hours after initiation of dosing. 12.3 Pharmacokinetics Absorption In healthy adults, subcutaneous injection of FUROSCIX (80 mg furosemide injection via the ReadyFlow), the bioavailability was 107.3% (90% CI: 103.9, 110.8) relative to 80 mg intravenous furosemide (two 40‑mg bolus doses separated by 120 minutes) with a median (min-max) T max of 0.75 (0.5-1.5) hours. The pharmacokinetic parameters of FUROSCIX following subcutaneous injection via the ReadyFlow autoinjector are presented in Table 1 below: Table 1: Pharmacokinetic Data of FUROSCIX Following Subcutaneous Injection via the ReadyFlow Autoinjector (n = 19) Dose C max (ng/mL) AUC t (ng×hr/mL) T 1/2 (hr) AUC ∞ (ng×hr/mL) FUROSCIX: 80 mg injection via the ReadyFlow 4,530 ± 1,500 12,500 ± 4,010 2.2 ± 0.3 12,700 ± 4,120 Furosemide administered as 2 x 40 mg bolus doses intravenously, separated by 120 minutes (total dose: 80 mg furosemide) 10,100 ± 2,810 11,700 ± 3,450 1.9 ± 0.4 11,800 ± 3,510 In adult patients with NYHA Class II-III congestive heart failure, subcutaneous infusion of FUROSCIX (30 mg furosemide over the first hour followed by 12.5 mg per hour for the subsequent 4 hours, 80 mg furosemide total), the bioavailability was 99.6% (90% CI: 94.8, 104.8) relative to 80 mg intravenous furosemide (two 40-mg bolus doses separated by 120 minutes) with a median T max (min-max) of 4 (1.00 - 5.08) hours. The pharmacokinetic parameters of FUROSCIX following subcutaneous infusion via the On-body Infusor are presented in Table 2 below: Table 2: Pharmacokinetic Data of FUROSCIX Following Subcutaneous Infusion via the On-body Infusor (n = 15) Dose Cmax (ng/mL) AUCt (ng×hr/mL) T1/2 (hr) AUC∞ (ng×hr/mL) FUROSCIX: 30 mg subcutaneously infused over the first hour followed by 12.5 mg per hour for the subsequent 4 hours (total dose: 80 mg furosemide) 2,040 ± 449 13,000 ± 4,000 3.2 ± 0.9 13,100 ± 4,010 Furosemide administered as 2 x 40 mg bolus doses intravenously, separated by 120 minutes (total dose: 80 mg furosemide) 8,580 ± 2,540 13,000 ± 4,050 2.6 ± 0.3 13,200 ± 4,170 The impact of subcutaneous edema at the administration site of FUROSCIX on drug absorption is unknown. Distribution Furosemide is extensively bound to plasma proteins, mainly to albumin. Plasma concentrations ranging from 1 mcg per mL to 400 mcg per mL are 91% to 99% bound in healthy individuals. The unbound fraction averages 2.3% to 4.1% at therapeutic concentrations. Elimination The terminal half-life of furosemide is approximately 2 hours. Metabolism Furosemide glucuronide is the only or at least the major biotransformation product of furosemide in humans. Excretion Significantly more furosemide is excreted in urine following the intravenous injection than after the tablet or oral solution. Specific Populations Pediatric Patients FUROSCIX was not evaluated in a pediatric clinical study. Based on population pharmacokinetic modeling and simulation, pediatric patients aged 6 to <17 years and weighing 43 kg and above are predicted to have comparable exposures to adult patients following FUROSCIX administration using the FUROSCIX On-body Infusor. Geriatric Patients Furosemide binding to albumin may be reduced in elderly patients. Furosemide is predominantly excreted unchanged in the urine. The renal clearance of furosemide after intravenous administration in older healthy male subjects (60 to 70 years of age) is significantly less than in younger healthy male subjects (20 to 35 years of age). The initial diuretic effect of furosemide in older subjects is decreased relative to younger subjects [see Use in Specific Populations ( 8.5 )] . 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Furosemide was tested for carcinogenicity by oral administration in one strain of mice and one strain of rats. A small but significantly increased incidence of mammary gland carcinomas occurred in female mice at a dose approximately 8 times a human i.v. dose of 80 mg based on BSA and oral bioavailability corrections. There were marginal increases in uncommon tumors in male rats at a dose of 15 mg per kg (slightly greater than the maximum human dose) but not at 30 mg per kg. Mutagenesis Furosemide was devoid of mutagenic activity in various strains of Salmonella typhimurium when tested in the presence or absence of an in vitro metabolic activation system, and questionably positive for gene mutation in mouse lymphoma cells in the presence of rat liver S9 at the highest dose tested. Furosemide did not induce sister chromatid exchange in human cells in vitro , but other studies on chromosomal aberrations in human cells in vitro gave conflicting results. In Chinese hamster cells it induced chromosomal damage but was questionably positive for sister chromatid exchange. Studies on the induction by furosemide of chromosomal aberrations in mice were inconclusive. The urine of rats treated with this drug did not induce gene conversion in Saccharomyces cerevisiae . Impairment of Fertility Furosemide produced no impairment of fertility in male or female rats, at 100 mg per kg per day (the maximum effective diuretic dose in the rat), approximately 7 times a human i.v. dose of 80 mg based on BSA and oral bioavailability corrections. Table text from source: Table 1: Pharmacokinetic Data of FUROSCIX Following Subcutaneous Injection via the ReadyFlow Autoinjector (n = 19) | Dose | C max(ng/mL) | AUC t (ng×hr/mL) | T 1/2(hr) | AUC ∞(ng×hr/mL) | FUROSCIX: 80 mg injection via the ReadyFlow | 4,530 ± 1,500 | 12,500 ± 4,010 | 2.2 ± 0.3 | 12,700 ± 4,120 | Furosemide administered as 2 x 40 mg bolus doses intravenously, separated by 120 minutes (total dose: 80 mg furosemide) | 10,100 ± 2,810 | 11,700 ± 3,450 | 1.9 ± 0.4 | 11,800 ± 3,510 Table 2: Pharmacokinetic Data of FUROSCIX Following Subcutaneous Infusion via the On-body Infusor (n = 15) | Dose | Cmax(ng/mL) | AUCt(ng×hr/mL) | T1/2 (hr) | AUC∞(ng×hr/mL) | FUROSCIX: 30 mg subcutaneously infused over the first hour followed by 12.5 mg per hour for the subsequent 4 hours (total dose: 80 mg furosemide) | 2,040 ± 449 | 13,000 ± 4,000 | 3.2 ± 0.9 | 13,100 ± 4,010 | Furosemide administered as 2 x 40 mg bolus doses intravenously, separated by 120 minutes (total dose: 80 mg furosemide) | 8,580 ± 2,540 | 13,000 ± 4,050 | 2.6 ± 0.3 | 13,200 ± 4,170 Table 1: Pharmacokinetic Data of FUROSCIX Following Subcutaneous Injection via the ReadyFlow Autoinjector (n = 19) | Dose | C max(ng/mL) | AUC t (ng×hr/mL) | T 1/2(hr) | AUC ∞(ng×hr/mL) | FUROSCIX: 80 mg injection via the ReadyFlow | 4,530 ± 1,500 | 12,500 ± 4,010 | 2.2 ± 0.3 | 12,700 ± 4,120 | Furosemide administered as 2 x 40 mg bolus doses intravenously, separated by 120 minutes (total dose: 80 mg furosemide) | 10,100 ± 2,810 | 11,700 ± 3,450 | 1.9 ± 0.4 | 11,800 ± 3,510 Table 2: Pharmacokinetic Data of FUROSCIX Following Subcutaneous Infusion via the On-body Infusor (n = 15) | Dose | Cmax(ng/mL) | AUCt(ng×hr/mL) | T1/2 (hr) | AUC∞(ng×hr/mL) | FUROSCIX: 30 mg subcutaneously infused over the first hour followed by 12.5 mg per hour for the subsequent 4 hours (total dose: 80 mg furosemide) | 2,040 ± 449 | 13,000 ± 4,000 | 3.2 ± 0.9 | 13,100 ± 4,010 | Furosemide administered as 2 x 40 mg bolus doses intravenously, separated by 120 minutes (total dose: 80 mg furosemide) | 8,580 ± 2,540 | 13,000 ± 4,050 | 2.6 ± 0.3 | 13,200 ± 4,170

13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Furosemide was tested for carcinogenicity by oral administration in one strain of mice and one strain of rats. A small but significantly increased incidence of mammary gland carcinomas occurred in female mice at a dose approximately 8 times a human i.v. dose of 80 mg based on BSA and oral bioavailability corrections. There were marginal increases in uncommon tumors in male rats at a dose of 15 mg per kg (slightly greater than the maximum human dose) but not at 30 mg per kg. Mutagenesis Furosemide was devoid of mutagenic activity in various strains of Salmonella typhimurium when tested in the presence or absence of an in vitro metabolic activation system, and questionably positive for gene mutation in mouse lymphoma cells in the presence of rat liver S9 at the highest dose tested. Furosemide did not induce sister chromatid exchange in human cells in vitro , but other studies on chromosomal aberrations in human cells in vitro gave conflicting results. In Chinese hamster cells it induced chromosomal damage but was questionably positive for sister chromatid exchange. Studies on the induction by furosemide of chromosomal aberrations in mice were inconclusive. The urine of rats treated with this drug did not induce gene conversion in Saccharomyces cerevisiae . Impairment of Fertility Furosemide produced no impairment of fertility in male or female rats, at 100 mg per kg per day (the maximum effective diuretic dose in the rat), approximately 7 times a human i.v. dose of 80 mg based on BSA and oral bioavailability corrections.

16 HOW SUPPLIED/STORAGE AND HANDLING FUROSCIX injection is a sterile, clear, colorless to slightly yellow, non-pyrogenic liquid supplied either in a single-dose autoinjector for subcutaneous injection or in a single-dose prefilled cartridge for subcutaneous infusion co-packaged with the On-body Infusor. Carton containing one 80 mg/mL single-dose prefilled autoinjector NDC 71767-111-01 Carton containing one 80 mg/10 mL (8 mg/mL) prefilled cartridge co-packaged with one On-body Infusor NDC 71767-100-01 Store between 20°C and 25°C (68°F and 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [See USP Controlled Room Temperature]. Do not refrigerate or freeze. Protect from light. Do not remove the FUROSCIX ReadyFlow or cartridge for use in the On-body Infusor from carton until it is ready for use. Do not use if you see particles in the solution or if the solution is discolored or cloudy. Protect the On-body Infusor for FUROSCIX from water. Table text from source: | Carton containing one 80 mg/mL single-dose prefilled autoinjector | NDC 71767-111-01 | Carton containing one 80 mg/10 mL (8 mg/mL) prefilled cartridge co-packaged with one On-body Infusor | NDC 71767-100-01

17 PATIENT COUNSELING INFORMATION Advise the patient and/or caregiver to read the FDA-approved patient labeling [see FDA-approved Instructions for Use ] . Advise patients that they should not allow the On-body Infusor to come into contact with water or other fluids. Advise patients and/or caregivers to check the device for alarms to ensure a complete dose is administered [see Warnings and Precautions ( 5.5 )] . Fluid, Electrolyte, and Metabolic Abnormalities Advise patients that they may experience symptoms from excessive fluid and/or electrolyte losses. The postural hypotension that sometimes occurs can usually be managed by getting up slowly. Potassium supplements and/or dietary measures may be needed to control or avoid hypokalemia [see Warnings and Precautions ( 5.1 )] . Advise patients that furosemide may increase blood glucose levels and thereby affect urine glucose tests [see Warnings and Precautions ( 5.1 )]. Photosensitivity The skin of some patients may be more sensitive to the effects of sunlight while taking furosemide [see Adverse Reactions ( 6 )] . Advise hypertensive patients to avoid medications that may increase blood pressure, including over-the-counter products for appetite suppression and cold symptoms [see Drug Interactions ( 7.1 )] . For more information about FUROSCIX, go to www.FUROSCIX.com or call call 1-877-323-8505 FUROSCIX ® (furosemide injection) for subcutaneous use Manufactured for: MannKind Corporation 25 Mall Road Burlington, MA 01803 Patent: www.mannkindcorp.com/patent-notices FUROSCIX, FUROSCIX READYFLOW, and MANNKIND are trademarks of MannKind Corporation © 2026 MannKind Corporation REG-0018 Rev 05 MNKD Logo

INSTRUCTIONS FOR USE Model/REF # FUR-80W5 Instructions For Use On-Body Infusor for FUROSCIX® [fue roe’ six] (furosemide injection) for subcutaneous use Single-Use On-Body Infusor and 80 mg/10 mL (8 mg/mL) Prefilled Cartridge This Instructions for Use contains information about how to prepare and use FUROSCIX On-Body Infusor. Before Starting Read this Instructions for Use before using the FUROSCIX On-Body Infusor for the first time. You or a caregiver should receive training before using the Furoscix On-Body Infusor. Always wash your hands before starting. The FUROSCIX On-Body Infusor will deliver a fixed dose of 80 mg of furosemide over about 5 hours. The FUROSCIX On-Body Infusor delivers the medicine just under the skin (subcutaneously). When the FUROSCIX On-Body Infusor is started, a small needle sticks into the skin to deliver the medicine. The on-body Infusor signals when all the medicine has been delivered. When the on-body Infusor is removed from the skin, a needle cover will extend over the needle to protect from an accidental needle stick. Parts of the FUROSCIX On-Body Infusor and Prefilled Cartridge Important Information The on-body Infusor and prefilled cartridge are not made with natural rubber latex. The infusion will last about 5 hours. During this time, you should limit your activity so that your bending movements are limited. Wearing the Infusor while riding in a car or flying in an airplane is not recommended. You should notice an increase in urine production in about an hour after the infusion is started and may need to make frequent bathroom visits. Be sure you have access to a bathroom for up to 8 hours after starting the infusion. If you do not notice the need to go to the bathroom, call your healthcare provider. The on-body Infusor can only be used with the prefilled FUROSCIX cartridge supplied in the kit. Do not use any other cartridges or medicines inside the on-body Infusor. Do not apply lotions, oils, or ointments to the adhesion area of the abdomen prior to applying the on-body Infusor to the abdomen. Do not use the on-body Infusor if the packaging appears to be opened, or if the on-body Infusor has been dropped or appears to be broken or damaged. Do not use the on-body Infusor within 12 inches of mobile phones, tablets, computers or wireless accessories (for example: TV remote control, Bluetooth computer keyboard or mouse). Do not use the on-body Infusor or prefilled cartridge after the expiration date on the carton. Do not use the prefilled cartridge if the liquid is discolored or cloudy. The liquid in the prefilled cartridge should be clear to slightly yellow in color. Do not use the on-body Infusor in or around an MRI machine. Do not take the on-body Infusor off your skin while it is infusing, unless there is an emergency or a device error. Removing the on-body Infusor before the infusion is done will result in a partial dose. The on-body Infusor will stop infusing and it cannot be restarted. Do not apply a new on-body Infusor unless instructed to do so by your healthcare provider. Do not reuse the on-body Infusor. The on-body Infusor is for single use only. Do not let the on-body Infusor get wet from water or any other liquids. Do not shower, bathe, swim or do activities that may make you sweat while wearing the on-body Infusor. It contains parts that should not get wet. Call your healthcare provider or scPharmaceuticals at 1-855-SCPHARMA (1-855-727-4276) if you have any questions. Storage Information The FUROSCIX On-Body Infusor and prefilled cartridge should be stored at controlled room temperature between 68°F to 77°F (20°C to 25°C) (see Figure B). Do not refrigerate or freeze. Keep the FUROSCIX prefilled cartridge in the original carton to protect from light or physical damage until you are ready to use. Keep the FUROSCIX On-Body Infusor and prefilled cartridge out of the reach of children. Prepare for the Infusion STEP 1 Wash Hands, Check Expiration Date and Remove Supplies from Carton ​ 1.1 Wash your hands before using the on-body Infusor (Figure C). 1.2 Check the expiration date on the FUROSCIX On-Body Infusor carton (see Figure D). Do not use if the expiration date has passed. 1.3 Open the carton and peel away the white paper cover. Remove the plastic cover from the clear tray. Remove supplies from the carton and packaging (see Figure E). Do not use the on-body Infusor or prefilled cartridge if packaging appears to have been previously opened or damaged. 1.4 Gather all materials needed for your injection, on a clean, well-lit work surface (Figure F): On-body Infusor and prefilled cartridge (Included) Instructions For Use (Included) Alcohol wipes (Included) Clippers (if needed) (Not included) Sharps disposal container (Not included) STEP 2 Check On-Body Infusor and Prefilled Cartridge 2.1 Check the on-body Infusor and prefilled cartridge for any damage (see Figure G). Do not use the on-body Infusor or prefilled cartridge if either item appears to be damaged. Do not touch the blue start button until the on-body Infusor is on the skin and you are ready to begin the infusion. Do not touch or fully open the cartridge holder until you are ready to load the cartridge. 2.2 Check the liquid medicine in the prefilled cartridge (see Figure H). The liquid in the prefilled cartridge should be clear to slightly yellow. Do not use the prefilled cartridge if the liquid is discolored or cloudy. Call scPharmaceuticals at: 1-855-SCPHARMA (1-855-727-4276) or call your healthcare provider. STEP 3 Load Prefilled Cartridge into the On-Body Infusor 3.1 Clean the tip (small end) of the prefilled cartridge with an alcohol wipe (see Figure I). Do not continue with the process of opening the cartridge holder all the way or loading the prefilled cartridge until you are ready to begin the infusion. 3.2 Open the cartridge holder all the way to turn on the on-body Infusor. The on-body Infusor “beeps” and the indicator light will begin blinking blue (see Figure J). Note: Complete steps 3.3 through 6.1 within 30 minutes of fully opening the cartridge holder or the Infusor will alarm and cannot restart. 3.3 Insert the prefilled cartridge into the cartridge holder with the tip pointed down (see Figure K). Note: The prefilled cartridge should slide into the cartridge holder easily. If it does not slide in easily, check the prefilled cartridge to make sure the tip is pointed down and try again. Do not press the blue start button until on-body Infusor is applied to skin and you are ready to begin the infusion. 3.4 Close the cartridge holder all the way until it is even with the rest of the on-body Infusor (see Figure L). You may hear a “click” sound when it is closed. Note: If the indicator light blinks red and the on-body Infusor "beeps", the on-body Infusor has experienced an internal error. Do not use the on-body Infusor (see On-Body Infusor Alarm section). Apply the On-Body Infusor STEP 4 Select and Prepare Application Site 4.1 Select one site on the stomach on either side of the belly button (navel). The site should be a flat area below the rib cage and above the belt line (see Figure M). Do not select a site where the skin is irritated or broken. Do not apply lotions, oils or ointments to the adhesion area of the abdomen. Do not select a site where belts, waistbands or other types of clothing may rub against, disturb, or dislodge the on-body Infusor. Note : Rotate application site (side of the stomach) each time if told by your healthcare provider to repeat dose. 4.2 The site should be hairless or nearly hairless. If needed, remove excess hair by clipping or shaving the hair before applying the on-body Infusor (see Figure N). 4.3 Wipe the skin where the on-body Infusor will be applied with an alcohol wipe and allow area to dry (see Figure O). STEP 5 Apply the On-Body Infusor 5.1 Pick up the on-body Infusor. Peel away the adhesive liner by grasping the white tab and pulling it away from the blue tab/adhesive backing (see Figure P). Do not touch the sticky (adhesive) part of the on-body Infusor with your fingers or let it touch any objects or surfaces before the Infusor is placed on the skin. 5.2 Apply the on-body Infusor to the chosen skin site while standing or sitting up straight. Position the on-body Infusor so that the cartridge window and the indicator light can be seen during the infusion (see Figure Q). Do not bend over when applying the on-body Infusor. 5.3 Press the on-body Infusor firmly onto the skin and hold it for several seconds (see Figure R). Then rub your finger over the edges of the adhesive to get it to stick well. Do not touch the blue start button until you are ready to start the infusion (see Step 6). Do not remove and reapply on-body Infusor. The on-body Infusor adhesive might not work as well. Start the Infusion STEP 6 Start the Infusion 6.1 Firmly press and release the blue start button to begin the infusion (see Figure S). The on-body Infusor will stick a very small needle just under the skin and begin delivering the medicine. The indicator light will start blinking green and the on-body Infusor "beeps", signifying that the infusion has begun. Note: At the start of the infusion, you may also hear the on-body Infusor motor running for several seconds. STEP 7 Allow Medicine to Deliver for 5 Hours 7.1 Relax during the delivery period. The on-body Infusor should remain on the skin until the delivery is complete. Do not exercise or take part in activities that might result in the on-body Infusor falling off. Take care not to bump the on-body Infusor while wearing it. It takes about 5 hours for the on-body Infusor to deliver all of the medicine. During the infusion, the indicator light will continue to blink green periodically, signifying that the infusion is running (see Figure T). Note: If the on-body Infusor falls off or if the indicator light begins blinking red, call your healthcare provider right away (see On-Body Infusor Alarm section). Do not reapply or reuse the on-body Infusor. Do not apply a new on-body Infusor unless instructed to do so by your healthcare provider. If You Have to Stop the Infusion Due to An Emergency, Do the Following: Remove the on-body Infusor from the skin (see Step 8). It will immediately stop infusing and the on-body Infusor will deactivate. Do not reuse the on-body Infusor. After the on-body Infusor is removed, it can no longer be used. Call your healthcare provider for further instructions. Remove and Dispose of the On-Body Infusor STEP 8 When Infusion is Complete, Remove the On-Body Infusor from the Skin 8.1 The infusion is complete and the on-body Infusor is ready to be removed when (see Figure U): The indicator light turns solid green. The on-body Infusor "beeps". The white plunger rod fills the cartridge window all the way. Note: If indicator light begins blinking red instead of green and the on-body Infusor “beeps”, call your healthcare provider (see On-Body Infusor Alarm section). 8.2 Peel the on-body Infusor off the skin by holding the skin down and pulling on the blue tab (see Figure V). When the on-body Infusor is removed, the indicator light will turn off, the needle cover will extend over the needle to protect against accidental needle sticks, and the on-body Infusor will turn off. Note: You might have some discomfort after you remove the adhesive. This discomfort should quickly go away. However, some redness of the skin may remain. 8.3 Check the infusion site. If there is any bleeding use a cotton ball or apply a small adhesive bandage. STEP 9 Throw Away (Dispose) of Used On-Body Infusor 9.1 Dispose of the used FUROSCIX On-Body Infusor and prefilled cartridge together into an FDA-cleared sharps container (see Figure W). Do not attempt to remove the cartridge from the on-body Infusor; it cannot be removed. Do not throw away the used on-body Infusor into household trash. If you do not have a FDA-cleared sharps disposal container, you may use a household container that is: made of a heavy-duty plastic, can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out, upright and stable during use, leak-resistant, and properly labeled to warn of hazardous waste inside the container. When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used Needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal. Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle the on-body Infusor or sharps disposal container or throw them into household trash. Important: Always keep the sharps disposal container out of the reach of children. For more information refer to: http://www.safeneedledisposal.org Infusor Alarm What happened? The Indicator light blinks red and the on-body Infusor "beeps" (see Figure X). What does it mean? There has been an internal error or the on-body Infusor came off the skin during the infusion. What to do? Stop using the on-body Infusor. If the on-body Infusor is on the skin, carefully remove it. Call your healthcare provider for further instructions. Do not reapply or reuse the on-body Infusor. It can no longer be used. Do not apply a new on-body Infusor unless instructed to do so by your healthcare provider. Symbols Legend scPharmaceuticals, Inc. 25 Mall Road, Suite 203, Burlington, MA 01803 1-855-SCPHARMA (1-855-727-4276) This Instructions for Use has been approved by the U.S. Food and Drug Administration. Issued: 10/2023 Reg-0017 Rev 01 Figure A Figure B c D E F G H I J K L M N O P Q R S T U V W X Symb INSTRUCTIONS FOR USE FUROSCIX ReadyFlow™ [fue roe’ six] (furosemide injection) for subcutaneous use Single-dose autoinjector 80 mg/mL This Instructions for Use contains information on how to use the FUROSCIX ReadyFlow autoinjector to inject an 80 mg dose of furosemide under the skin (subcutaneous). Read this Instructions for Use before using the FUROSCIX ReadyFlow autoinjector. Before using the FUROSCIX ReadyFlow autoinjector, your healthcare provider should show you how to use it the right way. If you have any questions, ask your healthcare provider. INSTRUCTIONS FOR USE Important Information You Need to Know Before Using the FUROSCIX ReadyFlow autoinjector The autoinjector is for single use only. The autoinjector is for subcutaneous (under the skin) injection into the stomach area (abdomen) only. Before injection Do not remove the blue Cap until you are ready to inject (see Step 6). Do not touch or push on the Needle cover. The needle is covered by the grey Needle cover and will not be seen. Do not use in extreme heat or cold. During injection Only inject into the stomach area (abdomen). Do not inject into any other area of the body. Do not lift the autoinjector from your skin before the yellow Plunger rod has stopped moving and fills the Viewing window. If the yellow Plunger rod does not move or does not fill the Viewing window, contact your healthcare provider. If you lift the autoinjector too early or do not press the autoinjector firmly against the skin for the entire injection, the Medicine may appear on the skin or squirt from the needle, and you may not get your full dose of FUROSCIX. If you believe you have not received a full dose, contact your healthcare provider. After injection You should notice an increase in urine production about an hour after the injection and may need to make frequent bathroom visits. Be sure you have access to a bathroom for up to 6 hours after the injection. If you do not notice the need to use the bathroom, contact your healthcare provider. Storing FUROSCIX ReadyFlow autoinjector The autoinjector should be stored at room temperature between 68°F and 77°F (20°C and 25°C). Do not refrigerate or freeze. Keep the autoinjector in the original carton until ready to use to protect from light. Keep the autoinjector and all medicines out of the reach of children. Preparing to Inject 1. Gather supplies Gather all supplies needed for your injection on a clean, well-lit work surface: FUROSCIX ReadyFlow autoinjector Other supplies (not included) ◦ Alcohol wipe ◦ Cotton balls or gauze ◦ Small bandage ◦ Sharps disposal container (see Step 9) 2. Inspect autoinjector Inspect the autoinjector and make sure: the Medicine in the Viewing window is clear and colorless to slightly yellow the Expiration date has not passed there are no signs of cracks or damage Do not use the autoinjector if you see particles in the Medicine. Do not use the autoinjector if the Medicine is discolored or cloudy. Do not use the autoinjector after the Expiration date. Do not use the autoinjector if there are signs of cracks or damage. 3. Wash hands Wash your hands with soap and water before using the autoinjector. 4. Select injection site on the stomach area (abdomen) Select an injection site on the stomach area only , at least two inches away from the belly button (navel). Do not select a site where the skin is irritated or broken. Avoid areas with scars or stretch marks. Make sure you switch areas on the stomach area each time you give an injection. 5. Clean the injection site Wipe the injection site with an alcohol wipe and allow the area to dry. Do not blow on or touch the cleaned area again before injecting. Injecting FUROSCIX 6. Remove Cap Pull the blue Cap straight off and throw away (dispose of) Cap. When the Cap is removed, use the autoinjector right away. Do not put the Cap back onto the autoinjector. Do not touch or push on the grey Needle cover (needle inside). 7. Place autoinjector Hold the autoinjector at 90 degrees with the grey Needle cover flat against the clean stomach area injection site. Make sure you can see the Viewing window. 8. Deliver injection a. Firmly push and hold the autoinjector against stomach area until the yellow Plunger rod stops moving. This may take about 10 seconds. You may or may not hear 2 clicks during the injection. Do not lift the autoinjector while the yellow Plunger rod is moving. If the yellow Plunger rod does not start moving, press the autoinjector more firmly against your skin . b. Check that the yellow Plunger rod has stopped moving and fills the Viewing window. Do not lift the autoinjector before the injection is done. If the Viewing window does not turn completely yellow, or if you see Medicine coming out of the autoinjector, you might not have received a full dose. Contact your healthcare provider. C. When the injection is complete, lift the autoinjector. The grey Needle cover will automatically extend and lock out over the needle. Do not reuse the autoinjector. You cannot stop and restart an injection. It is for single use only. If you see some blood at the injection site, this is normal. Lightly dab with a cotton ball and apply a small bandage. ​ After Injecting 9. Throw away (dispose of) the autoinjector Put your used autoinjector into an FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) the autoinjector in your household trash. If you do not have a FDA-cleared sharps disposal container, you may use a household container that: is made of a heavy-duty plastic, can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out, is upright and stable during use, is leak-resistant, and is properly labeled to warn of hazardous waste inside the container. When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal Do not dispose of your sharps disposal container in household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container. Keep the sharps disposal container out of the reach of children. 10. Expect increased need to urinate Urine production should increase about an hour after the injection for up to 6 hours. If you do not notice the need to use the bathroom, contact your healthcare provider For additional resources call 1-877-323-8505 © 2026 MannKind Corporation, 25 Mall Road, Burlington, MA 01803 USA FUROSCIX READYFLOW is a trademark of MannKind Corporation Patent: www.mannkindcorp.com/patent-notices This Instructions for Use has been approved by the U.S. Food and Drug Administration. Approved: 7/2026 REG-0021 R06 Fig 1 Fig 2 Fig 3 Fig 4 Fig 5 Fig 6 Fig 7 Fig 8 Fig 9 Fig 10 Fig 11 Fig 12 Fig 13 Fig 14 Table text from source: | Preparing to Inject1. Gather suppliesGather all supplies needed for your injection on a clean, well-lit work surface:FUROSCIX ReadyFlow autoinjectorOther supplies (not included)◦ Alcohol wipe◦ Cotton balls or gauze◦ Small bandage◦ Sharps disposal container (see Step 9) | | 2. Inspect autoinjectorInspect the autoinjector and make sure:the Medicine in the Viewing window is clear and colorless to slightly yellowthe Expiration date has not passedthere are no signs of cracks or damageDo not use the autoinjector if you see particles in the Medicine. Do not use the autoinjector if the Medicine is discolored or cloudy. Do not use the autoinjector after the Expiration date. Do not use the autoinjector if there are signs of cracks or damage. | | 3. Wash handsWash your hands with soap and water before using the autoinjector. | | 4. Select injection site on the stomach area (abdomen)Select an injection site on the stomach area only, at least two inches away from the belly button (navel). Do not select a site where the skin is irritated or broken. Avoid areas with scars or stretch marks. Make sure you switch areas on the stomach area each time you give an injection. | | 5. Clean the injection siteWipe the injection site with an alcohol wipe and allow the area to dry.Do not blow on or touch the cleaned area again before injecting. | | Injecting FUROSCIX6. Remove CapPull the blue Cap straight off and throw away (dispose of) Cap.When the Cap is removed, use the autoinjector right away.Do not put the Cap back onto the autoinjector. Do not touch or push on the grey Needle cover (needle inside). | | 7. Place autoinjectorHold the autoinjector at 90 degrees with the grey Needle cover flat against the clean stomach area injection site. Make sure you can see the Viewing window. | | 8. Deliver injectiona. Firmly push and hold the autoinjector against stomach area until the yellow Plunger rod stops moving. This may take about 10 seconds. You may or may not hear 2 clicks during the injection.Do not lift the autoinjector while the yellow Plunger rod is moving.If the yellow Plunger rod does not start moving, press the autoinjector more firmly against your skin . | | b. Check that the yellow Plunger rod has stopped moving and fills the Viewing window.Do not lift the autoinjector before the injection is done. If the Viewing window does not turn completely yellow, or if you see Medicine coming out of the autoinjector, you might not have received a full dose. Contact your healthcare provider. | | C. When the injection is complete, lift the autoinjector. The grey Needle cover will automatically extend and lock out over the needle.Do not reuse the autoinjector. You cannot stop and restart an injection. It is for single use only.If you see some blood at the injection site, this is normal. Lightly dab with a cotton ball and apply a small bandage. | | ​ After Injecting9. Throw away (dispose of) the autoinjectorPut your used autoinjector into an FDA-cleared sharps disposal container right away after use.Do not throw away (dispose of) the autoinjector in your household trash. If you do not have a FDA-cleared sharps disposal container, you may use a household container that:is made of a heavy-duty plastic,can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,is upright and stable during use,is leak-resistant, andis properly labeled to warn of hazardous waste inside the container.When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes.For more information about safe sharps disposal and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposalDo not dispose of your sharps disposal container in household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container. Keep the sharps disposal container out of the reach of children. | | 10. Expect increased need to urinateUrine production should increase about an hour after the injection for up to 6 hours. If you do not notice the need to use the bathroom, contact your healthcare provider |